📣 VC round data is live. Check it out!
- Public Comps
- Zimmer Biomet
Zimmer Biomet Valuation Multiples
Discover Zimmer Biomet's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Hologic, Sonova, United Imaging, Coloplast and more.
Zimmer Biomet Overview
About Zimmer Biomet
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Founded
2001
HQ

Employees
17.0K
Website
Financials (LTM)
EV
$23B
Valuation Multiples
Start free trialZimmer Biomet Financials
Zimmer Biomet reported last 12-month revenue of $8B and EBITDA of $3B.
In the same LTM period, Zimmer Biomet generated $6B in gross profit, $3B in EBITDA, and $2B in net income.
Revenue (LTM)
Zimmer Biomet P&L
In the most recent fiscal year, Zimmer Biomet reported revenue of $8B and EBITDA of $3B.
Zimmer Biomet is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 34%, and net margin of 20%.
Financial data powered by Morningstar, Inc.
Zimmer Biomet Stock Performance
Zimmer Biomet has current market cap of $16B, and enterprise value of $23B.
Market Cap Evolution
Zimmer Biomet's stock price is $83.75.
Zimmer Biomet share price increased by 1.7% in the last 30 days, and decreased by 8.2% in the last year.
Zimmer Biomet has an EPS (earnings per share) of $8.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23B | $16B | 1.0% | 1.7% | -7.4% | -8.2% | $8.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZimmer Biomet Valuation Multiples
Zimmer Biomet trades at 2.8x EV/Revenue multiple, and 8.3x EV/EBITDA.
EV / Revenue (LTM)
Zimmer Biomet Financial Valuation Multiples
As of June 4, 2026, Zimmer Biomet has market cap of $16B and EV of $23B.
Zimmer Biomet has a P/E ratio of 9.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zimmer Biomet Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Zimmer Biomet Margins & Growth Rates
Zimmer Biomet grew revenue by 4% but EBITDA decreased by 0% in the last fiscal year.
In the most recent fiscal year, Zimmer Biomet reported gross margin of 70%, EBITDA margin of 34%, and net margin of 20%.
Zimmer Biomet Margins
Zimmer Biomet Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Zimmer Biomet Operational KPIs
Zimmer Biomet's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Zimmer Biomet's Rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zimmer Biomet's Rule of X is 42% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Zimmer Biomet Competitors
Zimmer Biomet competitors include Hologic, Sonova, United Imaging, Coloplast, Solventum, Fisher & Paykel, Medpace, Penumbra, Smith & Nephew and Sartorius.
Most Zimmer Biomet public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | |||
| 3.6x | 3.6x | 13.4x | 13.2x | |||
| 6.5x | 6.0x | 35.4x | 34.5x | |||
| - | 4.0x | - | 12.2x | |||
| 2.2x | 2.2x | 7.0x | 9.5x | |||
| 9.2x | 9.2x | 26.6x | 26.6x | |||
| 4.8x | 4.6x | 21.7x | 21.0x | |||
| 8.6x | 8.2x | 46.5x | 43.8x | |||
This data is available for Pro users. Sign up to see all Zimmer Biomet competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Zimmer Biomet
Zimmer Biomet has acquired 19 companies to date.
Last acquisition by Zimmer Biomet was on July 14th 2025. Zimmer Biomet acquired Monogram Technologies for $168M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Zimmer Biomet
| Description | Monogram Technologies is a medical robotics company headquartered in Austin, Texas, advancing orthopedic surgery with its mBOTS robotic platform. The system enables precise bone milling for patient-matched knee implants during total joint replacements. Incorporated in 2021, it integrates AI-driven planning software with haptic feedback robotics to enhance surgical accuracy and outcomes. Monogram Technologies collaborates with hospitals for clinical trials in the United States. | Monogram Orthopedics is a Salt Lake City-based medical device company developing personalized knee implants using 3D printing and robotic surgery systems. Its platform integrates patient-specific imaging with automated design algorithms to produce custom load-bearing joint replacements. Launched in 2015, the technology aims to improve fit, reduce recovery time, and minimize wear in total knee arthroplasty procedures. Monogram holds patents for its digital workflow connecting preoperative planning to intraoperative robotics. | Paragon 28 is an Englewood-headquartered orthopedics company specializing in foot and ankle implants. It offers plates, screws, allografts, and fixation systems for forefoot, midfoot, hindfoot procedures and arthrodesis. The portfolio includes the Phantom Nail and Gorilla systems for trauma and reconstruction. Listed on the New York Stock Exchange since 2021, Paragon 28 distributes products to surgeons worldwide. | OrthoGrid Systems is a Scottsdale-based provider of AI-powered intraoperative imaging for orthopedic surgery. The platform corrects fluoroscopic distortions from C-arms in total hip arthroplasty, hip preservation, and trauma procedures, overlaying alignment grids for precise implant positioning. FDA-cleared since 2015, it integrates with standard operating rooms to improve reproducibility and reduce revision rates, serving hospitals across the United States and Europe. | |
| HQ Country | |||||
| HQ City | Austin, TX | Austin, TX | Denver, CO | Salt Lake City, UT | |
| Deal Date | 14 Jul 2025 | 14 Jul 2025 | 28 Jan 2025 | 7 Aug 2024 | |
| Valuation | $168M | $168M | $1B | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Zimmer Biomet acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Zimmer Biomet
Zimmer Biomet has invested in 1 company to date.
Latest investment by Zimmer Biomet was on June 5th 2024. Zimmer Biomet invested in Osteal Therapeutics in their $50M Series D round (EV/Revenue multiple available to Pro users).
Latest Investments by Zimmer Biomet
| Description | Osteal Therapeutics is a clinical-stage pharmaceutical company developing combination drug-device products for musculoskeletal infections. The firm's lead candidate targets implant-associated bone and joint infections using antibiotic-eluting implants. Osteal advances therapies through preclinical and Phase I/II trials in orthopedic surgery applications. |
| HQ Country | |
| HQ City | Dallas, TX |
| Deal Date | 5 Jun 2024 |
| Round | Series D |
| Raised | $50M |
| Investors | Gideon Strategic Partners; Huimei Capital; Johnson & Johnson Development Corporation; Zimmer Biomet |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Zimmer Biomet investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zimmer Biomet
| When was Zimmer Biomet founded? | Zimmer Biomet was founded in 2001. |
| Where is Zimmer Biomet headquartered? | Zimmer Biomet is headquartered in United States. |
| How many employees does Zimmer Biomet have? | As of today, Zimmer Biomet has over 17K employees. |
| Who is the CEO of Zimmer Biomet? | Zimmer Biomet's CEO is Ivan Tornos. |
| Is Zimmer Biomet publicly listed? | Yes, Zimmer Biomet is a public company listed on NYSE. |
| What is the stock symbol of Zimmer Biomet? | Zimmer Biomet trades under ZBH ticker. |
| When did Zimmer Biomet go public? | Zimmer Biomet went public in 2001. |
| Who are competitors of Zimmer Biomet? | Zimmer Biomet main competitors include Hologic, Sonova, United Imaging, Coloplast, Solventum, Fisher & Paykel, Medpace, Penumbra, Smith & Nephew, Sartorius. |
| What is the current market cap of Zimmer Biomet? | Zimmer Biomet's current market cap is $16B. |
| What is the current revenue of Zimmer Biomet? | Zimmer Biomet's last 12 months revenue is $8B. |
| What is the current revenue growth of Zimmer Biomet? | Zimmer Biomet revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Zimmer Biomet? | Current revenue multiple of Zimmer Biomet is 2.8x. |
| What is the current EBITDA of Zimmer Biomet? | Zimmer Biomet's last 12 months EBITDA is $3B. |
| What is Zimmer Biomet's EBITDA margin? | Zimmer Biomet's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Zimmer Biomet? | Current EBITDA multiple of Zimmer Biomet is 8.3x. |
| What is the current FCF of Zimmer Biomet? | Zimmer Biomet's last 12 months FCF is $1B. |
| What is Zimmer Biomet's FCF margin? | Zimmer Biomet's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Zimmer Biomet? | Current FCF multiple of Zimmer Biomet is 18.5x. |
| How many companies Zimmer Biomet has acquired to date? | As of June 2026, Zimmer Biomet has acquired 19 companies. |
| What was the largest acquisition by Zimmer Biomet? | $13B acquisition of BioMet on 24th April 2014 was the largest M&A Zimmer Biomet has done to date. |
| What companies Zimmer Biomet acquired? | Zimmer Biomet acquired BioMet, Paragon 28, LDR Holding, A&E Medical, Monogram Technologies, Monogram Orthopedics, Embody, Medtech SAS, ReLign, CD Diagnostics, and 9 other companies. |
| In how many companies Zimmer Biomet has invested to date? | As of June 2026, Zimmer Biomet has invested in 1 company. |
| What was the last Zimmer Biomet investment? | On 5th June 2024 Zimmer Biomet invested in Osteal Therapeutics, participating in a $50M Series D round, alongside Gideon Strategic Partners, Huimei Capital, and Johnson & Johnson Development Corporation. |
| In what companies Zimmer Biomet invested in? | Zimmer Biomet invested in Osteal Therapeutics. |
See public comps similar to Zimmer Biomet
Lists including Zimmer Biomet
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
